# Shilpa Medicare

Shilpa Medicare's wholly-owned subsidiary Shilpa Biocare Private Limited signed an exclusive European commercialization agreement with Finland-based Orion Corporation for Shilpa's recombinant human albumin (announced Q1 FY26 / late June 2026 disclosure) — Orion gains exclusive distribution,…

Source: https://en.bioecon.ru/companies/shilpa-medicare/
Updated: 2026-08-15

- Country: India
- Ticker: BSE:530549

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | The company receives development and regulatory milestone payments from Orion Corporation under their partnership agreements. | https://pharmafile.com/news/shilpa-medicare-and-orion-partner-expanding-into-european-market/, https://vbshilpa.com/pdf/Investor%20Presentation%20-%2026%20May%202025.pdf, https://www.businesswire.com/news/home/20260703259800/en/Orion-and-Shilpa-Medicare-Expand-Partnership-to-Develop-and-Supply-Nivolumab-Biosimilar-for-Europe, https://www.orionpharma.com/newsroom/all-news/releases/press-releases/2025/orion-announces-agreement-with-shilpa-medicare-for-recombinant-human-albumin-for-european-market/, https://www.orionpharma.com/newsroom/all-news/releases/press-releases/2026/orion-pharma-announces-agreement-with-shilpa-medicare-for-nivolumab-biosimilar-for-european-market/, https://www.vbshilpa.com/pdf/Investor%20presentation%20for%20the%20quarter%20ended%2031%20March%202026.pdf, https://www.vbshilpa.com/pdf/strategic%20partnership%20with%20Orion%20Corporation,%20Finland.pdf |
| Capacity | 200KL+ fermentation capacity, with capacities ranging from 5 KL to 50 KL for product vessels and 5 KL to 15 KL for buffer vessels. | https://vbshilpa.com/pdf/Investor%20Presentation%20-%2026%20May%202025.pdf, https://www.bseindia.com/xml-data/corpfiling/AttachHis/d8fbdf4d-cadc-4d71-b78c-359c6dc287ea.pdf, https://www.vbshilpa.com/pdf/Investor%20presentation%20for%20the%20quarter%20ended%2031%20March%202026.pdf |
| Certification | Manufacturing facilities hold various certifications including US FDA, EU GMP, WHO-GMP, TGA, PMDA, KFDA, ANVISA, COFEPRIS, and Health Canada. | https://vbshilpa.com/, https://vbshilpa.com/pdf/Investor%20Presentation%20-%2026%20May%202025.pdf, https://www.bseindia.com/xml-data/corpfiling/AttachHis/d8fbdf4d-cadc-4d71-b78c-359c6dc287ea.pdf, https://www.vbshilpa.com/pdf/Annual-report-results-2024-2025.pdf, https://www.vbshilpa.com/pdf/Investor%20presentation%20for%20the%20quarter%20ended%2031%20March%202026.pdf |
| Regulatory approval | The company maintains regulatory approvals from bodies including US FDA, EU GMP, PMDA, KFDA, and TGA. | https://vbshilpa.com/, https://vbshilpa.com/pdf/Investor%20Presentation%20-%2026%20May%202025.pdf, https://www.bseindia.com/xml-data/corpfiling/AttachHis/d8fbdf4d-cadc-4d71-b78c-359c6dc287ea.pdf, https://www.vbshilpa.com/pdf/Annual-report-results-2024-2025.pdf, https://www.vbshilpa.com/pdf/Investor%20presentation%20for%20the%20quarter%20ended%2031%20March%202026.pdf |
| Production site | Facilities include API Units 1 and 2 in Raichur, Formulations units in Jadcherla and Bangalore, and a Biologics site in Dharwad. | https://vbshilpa.com/, https://vbshilpa.com/pdf/Investor%20Presentation%20-%2026%20May%202025.pdf, https://www.bseindia.com/xml-data/corpfiling/AttachHis/d8fbdf4d-cadc-4d71-b78c-359c6dc287ea.pdf, https://www.vbshilpa.com/pdf/Investor%20presentation%20for%20the%20quarter%20ended%2031%20March%202026.pdf |
| Headcount | 1,059 total employees worldwide as of March 2026. | https://finance.yahoo.com/quote/SHILPAMED.NS/ |
| Revenue | INR 1,549 crores for the full year ended 31 March 2026. | https://www.bseindia.com/xml-data/corpfiling/AttachHis/d8fbdf4d-cadc-4d71-b78c-359c6dc287ea.pdf, https://www.bseindia.com/xml-data/corpfiling/AttachLive/33c87f15-3d6d-4a67-a887-1f40772259bf.pdf, https://www.vbshilpa.com/pdf/Investor%20presentation%20for%20the%20quarter%20ended%2031%20March%202026.pdf |

Independent sources: bseindia.com, businesswire.com, finance.yahoo.com, orionpharma.com, pharmafile.com, vbshilpa.com

## Technologies

- [Recombinant human serum albumin (rHSA)](https://en.bioecon.ru/technology/recombinant-human-serum-albumin/)